MX354409B - Derivados de estradiol sustituidos en 6 para uso en remielinización de axones nerviosos. - Google Patents

Derivados de estradiol sustituidos en 6 para uso en remielinización de axones nerviosos.

Info

Publication number
MX354409B
MX354409B MX2013010650A MX2013010650A MX354409B MX 354409 B MX354409 B MX 354409B MX 2013010650 A MX2013010650 A MX 2013010650A MX 2013010650 A MX2013010650 A MX 2013010650A MX 354409 B MX354409 B MX 354409B
Authority
MX
Mexico
Prior art keywords
remyelination
nerve axons
estradiol derivatives
substituted estradiol
substituted
Prior art date
Application number
MX2013010650A
Other languages
English (en)
Other versions
MX2013010650A (es
Inventor
G Yarger James
H Nye Steven
Original Assignee
Endece Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endece Llc filed Critical Endece Llc
Publication of MX2013010650A publication Critical patent/MX2013010650A/es
Publication of MX354409B publication Critical patent/MX354409B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se revela un método para remielinizar axones con un compuesto estradiol sustituido en 6 de la fórmula (ver Fórmula) El método se puede usar para tratar una variedad de enfermedades de desmielinización.
MX2013010650A 2011-03-21 2012-03-21 Derivados de estradiol sustituidos en 6 para uso en remielinización de axones nerviosos. MX354409B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161454873P 2011-03-21 2011-03-21
PCT/US2012/029973 WO2012129324A2 (en) 2011-03-21 2012-03-21 6-substituted estradiol derivatives for use in remyelination of nerve axons

Publications (2)

Publication Number Publication Date
MX2013010650A MX2013010650A (es) 2013-10-07
MX354409B true MX354409B (es) 2018-03-05

Family

ID=46877849

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010650A MX354409B (es) 2011-03-21 2012-03-21 Derivados de estradiol sustituidos en 6 para uso en remielinización de axones nerviosos.

Country Status (13)

Country Link
US (2) US9364486B2 (es)
EP (1) EP2688570B1 (es)
JP (1) JP6174563B2 (es)
KR (1) KR102080151B1 (es)
CN (2) CN106420767A (es)
AU (1) AU2012230974B2 (es)
BR (1) BR112013024168A2 (es)
CA (1) CA2830515C (es)
DK (1) DK2688570T3 (es)
ES (1) ES2561536T3 (es)
MX (1) MX354409B (es)
SG (1) SG193380A1 (es)
WO (1) WO2012129324A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013024168A2 (pt) * 2011-03-21 2017-07-11 Endece Llc derivados 6-substituídos de estradiol para aplicação na remielinização de axônios de nervos
WO2014064712A2 (en) * 2012-10-22 2014-05-01 Intas Pharmaceuticals Limited An improved process for the preparation of fulvestrant
BR112016021408A2 (pt) * 2014-03-19 2017-12-19 Endece Llc métodos para o tratamento da doença de alzheimer utilizando compostos derivados de 6-estradiol substituído
US20210024568A1 (en) * 2019-07-23 2021-01-28 Endece Llc Methods for modulation of lipoprotein lipase and apolipoprotein c2 expression and/or activity in the treatment of peripheral and central nervous system tissue disease states

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136160A (en) * 1977-08-17 1979-01-23 Cohen Steven R Specific assay for active demyelinization
JPH0193529A (ja) * 1987-10-05 1989-04-12 Mect Corp シアロシルコレステロールの脱髄性疾患治療剤
JPH01193529A (ja) 1988-01-27 1989-08-03 Yoshitsugu Takano 液体循環装置
CA2624269C (en) * 2005-09-30 2016-03-22 Endece, Llc Exemestane compounds, compositions and related uses thereof
US8168621B2 (en) * 2005-09-30 2012-05-01 Endece, Llc 6-substituted estradiol derivatives and methods of use
US10174070B2 (en) 2005-09-30 2019-01-08 Endece Llc 6-substituted estradiol derivatives and methods of use
WO2008067450A2 (en) * 2006-11-30 2008-06-05 Endece, Llc 6-alkoxyalkyl estradiol derivatives and methods of use
ES2605960T3 (es) 2010-09-14 2017-03-17 Endece, Llc Derivados de desmetil-estradiol 6-sustituido como agonistas del RE-beta
BR112013024168A2 (pt) * 2011-03-21 2017-07-11 Endece Llc derivados 6-substituídos de estradiol para aplicação na remielinização de axônios de nervos

Also Published As

Publication number Publication date
CN103501790B (zh) 2016-08-17
MX2013010650A (es) 2013-10-07
EP2688570A4 (en) 2014-09-10
WO2012129324A9 (en) 2012-11-15
CN103501790A (zh) 2014-01-08
US20160279144A1 (en) 2016-09-29
CN106420767A (zh) 2017-02-22
WO2012129324A2 (en) 2012-09-27
EP2688570B1 (en) 2015-11-18
AU2012230974B2 (en) 2016-05-12
AU2012230974A1 (en) 2013-09-26
BR112013024168A2 (pt) 2017-07-11
US9636348B2 (en) 2017-05-02
DK2688570T3 (en) 2015-12-21
KR102080151B1 (ko) 2020-02-21
US20120245131A1 (en) 2012-09-27
ES2561536T3 (es) 2016-02-26
KR20140074253A (ko) 2014-06-17
JP2014508807A (ja) 2014-04-10
CA2830515A1 (en) 2012-09-27
CA2830515C (en) 2015-09-15
EP2688570A2 (en) 2014-01-29
JP6174563B2 (ja) 2017-08-02
US9364486B2 (en) 2016-06-14
SG193380A1 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
EA030383B9 (ru) Бициклически замещённые урацилы, способы их получения, их применение, лекарственное средство и способ лечения с их применением
MX2015007916A (es) Peri-carbinoles.
PH12014500460A1 (en) Substituted annellated pyrimidine and the use thereof
MX2015005286A (es) Procedimiento para la preparación de derivados del ácido biliar.
PH12014501258A1 (en) Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
TN2014000122A1 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
NZ705705A (en) Ret inhibitor
WO2011123946A8 (en) Kinase inhibitors and method of treating cancer with same
MX2020005533A (es) Nuevo proceso para la preparacion de derivados de piperidinilo-azetidina e intermediarios de los mismos, en donde dichos compuestos son inhibidores de mek.
IN2015DN01151A (es)
MY184858A (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
PH12013502530A1 (en) Glioblastoma inhibiting compounds and their use
MX2014002936A (es) Nuevos derivados de acido betulinico con actividad antiviral.
MX2014005726A (es) Metodo de tratamiento de una enfermedad proliferativa.
BR112014014762A8 (pt) método para preparação de cisteína ou de um derivado desta usando uma nova o-fosferina sulfidrilase
IN2014MN01469A (es)
MX354409B (es) Derivados de estradiol sustituidos en 6 para uso en remielinización de axones nerviosos.
GB201107985D0 (en) Process
MX2013006658A (es) Métodos para producir y usar brasinoesteroides para promover el crecimiento, la reparación y mantenimiento del músculo esquelético y la piel.
NZ707773A (en) Methods of treating liver diseases
MX2014009084A (es) Derivados de pirimidooxazocina como inhibidores de mtor.
IN2014DN10658A (es)
IN2014KN01037A (en) Methods and compositions for the treatment of diabetes and related symptoms
IN2014DN07498A (es)
UA71930U (ru) Способ повышения эффективности вакцинации против гриппа у часто болеющих детей

Legal Events

Date Code Title Description
FG Grant or registration